SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-103344
Filing Date
2021-04-01
Accepted
2021-04-01 08:45:00
Documents
3
Period of Report
2021-04-01
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d166793d8k.htm 8-K 28779
2 EX-3.1 d166793dex31.htm EX-3.1 28893
3 EX-3.2 d166793dex32.htm EX-3.2 60746
  Complete submission text file 0001193125-21-103344.txt   120170
Mailing Address 134 COOLIDGE AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 134 COOLIDGE AVENUE 2ND FLOOR WATERTOWN MA 02472 617-393-5925
Pandion Therapeutics, Inc. (Filer) CIK: 0001807901 (see all company filings)

IRS No.: 833015614 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39381 | Film No.: 21796163
SIC: 2834 Pharmaceutical Preparations